Earnings Call Summary | Moleculin Biotech(MBRX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Moleculin Biotech(MBRX.US) Q1 2024 Earnings Conference
The following is a summary of the Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript:
以下是 Moleculin Biotech, Inc. (MBRX) 2024 年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
The company reported a decrease in Research & Development (R&D) expenses from $5.7 million to $4.3 million for Q1 2024.
General & Administrative (G&A) expenses also decreased from $2.6 million in the same period last year to $2.4 million for this quarter.
Moleculin Biotech had roughly $17 million in cash on hand for the quarter.
The market cap of Moleculin Biotech Inc. is estimated to be roughly $13 million.
该公司报告称，2024年第一季度的研发（R&D）支出从570万美元减少至430万美元。
一般和行政（G&A）支出也从去年同期的260万美元下降到本季度的240万美元。
Moleculin Biotech在本季度手头有大约1700万美元的现金。
据估计，Moleculin Biotech Inc.的市值约为1300万美元。
Business Progress:
业务进展：
The firm obtained patent protection for Annamycin, providing market exclusivity until 2040.
Clinical trials show Annamycin had a 60% CRC rate in second-line patients with zero reported cardiotoxicity.
Recruitment efforts continue for the ongoing MB-106 trial, prioritizing first-line patients.
Pivotal trials for the drug are projected to commence by the end of 2024, contingent on FDA approval.
The company suspended enrollment for second-line therapy in the 106 trial, as they've collected sufficient data for second-line pivotal trials.
An end-of-phase 2 meeting with the FDA is expected by the end of June.
An update is anticipated on the progress of the MB-106 trial in August.
该公司获得了安那霉素的专利保护，在2040年之前提供市场独家经营权。
临床试验显示，安那霉素在二线患者中的结直肠癌发生率为60％，心脏毒性报告为零。
正在进行的 MB-106 试验的招募工作仍在继续，优先考虑一线患者。
该药物的关键试验预计将于2024年底开始，但须视美国食品药品管理局的批准而定。
该公司暂停了106项试验的二线疗法的注册，因为他们已经为二线关键试验收集了足够的数据。
预计将在6月底之前与林业发展局举行第二阶段末会议。
预计 MB-106 试验的最新进展将在八月份公布。
More details: Moleculin Biotech IR
更多详情： 分子生物技术 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。